A5077453712- Lung Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Radiation Therapy and Dosimetry
- Hepatocellular Carcinoma Treatment and Prognosis
- Brain Metastases and Treatment
- Management of metastatic bone disease
- Neuroendocrine Tumor Research Advances
- Glioma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Cancer Immunotherapy and Biomarkers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Advances in Oncology and Radiotherapy
- Adrenal and Paraganglionic Tumors
- Effects of Radiation Exposure
- Advanced MRI Techniques and Applications
- Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Cancer, Hypoxia, and Metabolism
- MRI in cancer diagnosis
- Radiopharmaceutical Chemistry and Applications
Cancer Center Amsterdam
2018-2025
Amsterdam University Medical Centers
2018-2025
Vrije Universiteit Amsterdam
2015-2025
Amsterdam UMC Location Vrije Universiteit Amsterdam
2014-2024
University at Buffalo, State University of New York
2023
KPR Institute of Engineering and Technology
2023
University of Amsterdam
2006-2023
Leiden University Medical Center
2023
The Radiosurgery Society
2023
Radiation Oncology Associates
2008-2020
We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had response to chemotherapy.
The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites can be ablated. However, randomized data test this are lacking.We enrolled controlled primary malignancy and 1-5 metastatic lesions, amenable to stereotactic ablative radiotherapy (SABR). We stratified by the (1-3 v 4-5) in 1:2 ratio between palliative standard-of-care (SOC) treatments (arm 1) SOC plus SABR 2). used phase II screening...
The phase III PACIFIC trial compared durvalumab with placebo in patients unresectable, stage non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation was associated significant improvements the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) progression-free (PFS [blinded independent central review; RECIST v1.1]; HR, 0.52; 0.42 0.65; < .0001), manageable safety. We report updated,...
The effects of extra-pleural pneumonectomy (EPP) on survival and quality life in patients with malignant pleural mesothelioma have, to our knowledge, not been assessed a randomised trial. We aimed assess the clinical outcomes who were randomly assigned EPP or no context trimodal therapy Mesothelioma Radical Surgery (MARS) feasibility study.MARS was multicentre controlled trial 12 UK hospitals. Patients aged 18 years older had pathologically confirmed deemed fit enough undergo included. In...
BackgroundMost patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disease. We assessed thoracic radiotherapy for treatment of this patient group.MethodsWe did phase 3 randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 the UK, three Norway, one Belgium. enrolled WHO performance score 0–2 confirmed ES-SCLC responded to chemotherapy. They were randomly assigned (1:1) receive...
Stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) is associated with high local control rates. The impact of introducing SBRT in patients 75 years age or older was studied using a population-based registry.The Amsterdam Cancer Registry assessed three eras: 1999 to 2001 (period A, pre-SBRT); 2002 2004 B, some availability SBRT), and 2005 2007 C, full access SBRT). χ(2), Kaplan-Meier, Cox regression were used compare treatment patterns overall survival (OS)...
Purpose The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, versus etoposide-cisplatin TRT nonpemetrexed doublet therapy. Patients Methods with stage IIIA/B unresectable nonsquamous non–small-cell lung cancer randomly received (1:1) pemetrexed 500 mg/m 2 cisplatin 75 intravenously every 3 weeks for three cycles plus (60 to 66 Gy) four (arm A), or standard etoposide 50...
IntroductionIn the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated significant improvements in primary end points overall survival (OS) (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53–0.87; p 0.00251; data cutoff, March 22, 2018) and progression-free (PFS) (blinded independent central review; Response Evaluation Criteria Solid Tumors...
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control. Survival outcomes disease treated appear promising, but conclusions are limited by patient selection, the lack adequate controls in most studies. The goal this multicenter randomized phase II trial is to assess impact comprehensive program on overall survival...